Portage Biotech Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	10.55	23.35	2.77	3.15	6.17
Short-Term Investments	0.44	0	0	0.07	0.1
Cash & Cash Equivalents	10.99	23.35	2.77	3.22	6.27
Cash Growth	-52.95%	743.03%	-13.98%	-48.64%	-
Other Current Assets	2.69	1.48	2.18	0.57	0.28
Total Current Assets	13.68	24.83	4.95	3.79	6.55
Long-Term Investments	2.89	9.08	9.14	8.63	6.41
Goodwill and Intangibles	0	43.32	43.32	43.32	43.32
Other Long-Term Assets	82.56	117.42	117.45	117.42	117.43
Total Long-Term Assets	85.45	169.83	169.91	169.38	167.16
Total Assets	99.13	194.66	174.86	173.17	173.72
Accounts Payable	1.87	0.75	1.94	1.27	1.11
Current Debt	0	0	0.15	0.3	0.66
Other Current Liabilities	0	0.03	1.12	1	0.02
Total Current Liabilities	1.87	0.78	3.21	2.57	1.79
Long-Term Debt	11.31	0	0	3.36	3
Other Long-Term Liabilities	10.56	28.45	24.05	21.6	20.36
Total Long-Term Liabilities	21.87	28.45	24.05	24.97	23.36
Total Liabilities	23.73	29.23	27.26	27.53	25.16
Total Debt	11.31	0	0.15	3.66	3.66
Debt Growth	-	-	-95.90%	-0.05%	-
Retained Earnings	-159.62	-55.01	-38.14	-22.3	-16.97
Comprehensive Income	-4.33	0.96	0.96	0.96	0.08
Shareholders' Equity	76.05	121.21	101.45	96.53	99.67
Net Cash / Debt	-0.32	23.35	2.62	-0.44	2.61
Net Cash / Debt Growth	-	791.30%	-	-	-
Net Cash Per Share	-0.02	1.79	0.22	-0.04	0.54
Working Capital	11.81	24.05	1.74	1.23	4.76
Book Value Per Share	4.72	9.28	8.65	8.81	20.68

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).